Technology Designed to Improve siRNA Delivery

News
Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

Polyplus-transfection, a company that researches, develops, and commercializes drug-delivery solutions for biomolecules, created a new technology designed to enhance in vivo delivery of small interfering RNAs (siRNAs) when they are associated with a cationic polymer.

Strasbourg, France (Apr. 29)-Polyplus-transfection, a company that researches, develops, and commercializes drug-delivery solutions for biomolecules, created a new technology designed to enhance in vivo delivery of small interfering RNAs (siRNAs) when they are associated with a cationic polymer. The technology relies on the company’s "sticky siRNAs" (ssiRNAs), a class of siRNAs.

The technology adds complementary sequences to the opposite ends of interfering RNAs. When a cationic polymer such as the company’s “in vivo jetPEI” is present, ssiRNAs stick together end to end and form stable complexes. The technology ensures that siRNAs stay connected to their delivery reagent en route to the target cells and stimulate the RNA interference mechanism. The new strategy can be used with therapeutic siRNAs to treat cancers, allergies, viruses, and other diseases.

Cationic lipids have been a favored strategy for the delivery of therapeutic siRNAs. The ssiRNA technology enables cationic polymers to be used in this application.

In a company press release, Joëlle Bloch, CEO of Polyplus-transfection, said that “ssiRNAs are starting to be tested in vivo by several academic laboratories and biotechnology companies.”

RNA interference is a natural mechanism in cells that allows specific gene expression to be selectively silenced and regulated. This technique enables the treatment of genetic diseases and helps scientists understand the roles and interrelations of genes.

Transfection is the introduction of a gene or a siRNA into a cell for therapeutic purposes.

Recent Videos
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content